Skip to main content
 

John Wilcox

John Wilcox

I am a healthcare company founder and biomedical researcher with experience in leading the development and commercialization of medical devices, raising private capital and grant funding, and conducting preclinical trials, population health studies, and market research. My work is primarily focused on improving the care of people with diabetes and other chronic conditions through medical device innovation, having been inspired by my own diagnosis of type 1 diabetes on my ninth birthday and my everyday use of medical technology to live a healthy life. As the Co-Founder and Chief Executive Officer of Diatech Diabetes, Inc., I have led a team of biomedical engineers to design novel software algorithms to improve the safety of insulin dosing for infusion pumps and automated insulin delivery systems. I also have led FDA interactions via pre-submission meetings and Breakthrough Device Program applications. To fund this work, I have raised funding secured via the National Institutes of Health and Breakthrough T1D, the largest charitable funder and advocate for type 1 diabetes research worldwide. My role involves B2B and B2B2C client management, handling potential customers who engage in software license agreements for the use of Diatech’s products. I hold a very strong network within the medical device industry and international research organizations, including representatives of the NIH-NIDDK, Breakthrough T1D, the American Diabetes Association, and AdvaMed. My academic experience at Columbia University, Yale University, and Florida State University has resulted in the publication of works in the Journal of Diabetes Science & Technology and Diabetes Technology & Therapeutics related to topics on diabetes technology, psychology, and physiology. In addition to my work, I am incredibly passionate about advocacy as a charity marathon runner who has run the Boston, Chicago, and New York City Marathons while raising funds for medical research. Overall, I am an interdisciplinary professional known for rapid learning and consistently delivering results, even in challenging circumstances.

More News

  • Submissions for AHA Scientific Sessions Abstracts Opens April 9th

  • The Center for Health Technology & Innovations’ Monthly Newsletter

  • March Newsletter 2025